• By Deanna Kamienski, Beth Allan, Amanda Micklus, Steven Muntner, and Maureen Riordan
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced September through October 2014.
InSilixa raises $13mm in early-stage round
Molecular diagnostics start-up InSilixa Inc. raised $13mm in an early-stage financing led by PointGuard Ventures and Morningside Group, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.